Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Jake Nunn
AddedFeb 19, 2024
UpdatedMay 31, 2026
Jake Nunn

Jake Nunn

Board Member, Regulus Therapeutics

LinkedIn

Jake Nunn's Career

Regulus Therapeutics
Regulus Therapeutics

San Diego, CA, US

Board Member· Board
Trevena
Trevena

King of Prussia, PA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Jake Nunn's Career

Regulus Therapeutics
Regulus Therapeutics
Public$380.9M302007San Diego, CA, US
Board Member· Board

Leadership at Regulus Therapeutics

Pascale WitzPascale WitzBoard Member
Simos SimeonidisSimos SimeonidisBoard Member
William H. RastetterWilliam H. RastetterBoard Member
Stelios PapadopoulosStelios PapadopoulosBoard Member
Kathryn J CollierKathryn J CollierBoard Member
Jay HaganJay HaganBoard Member

Similar to Regulus Therapeutics

Regel TherapeuticsRegel TherapeuticsBoston, MA, USGene TherapyRegel TherapeuticsBoston, MA, US

Regel Therapeutics: Revolutionizing gene therapy and transforming patient outcomes with unique technology.

Pre-Seed · $1M14
Regor TherapeuticsRegor TherapeuticsBoston, MA, USBiotechnologyest. 2018Regor TherapeuticsBoston, MA, US · est. 2018

Regor: A global biotech leader innovating in oncology, metabolic and autoimmune diseases.

Series D · $140M8
Regulonix HoldingRegulonix HoldingTucson, AZ, USPain Treatmentsest. 2017Regulonix HoldingTucson, AZ, US · est. 2017

Regulonix: A biotech firm innovating non-opioid, chronic pain treatments via NaV1.7 channel targeting.

Seed · $2M8
Ionis PharmaceuticalsIonis PharmaceuticalsCarlsbad, CA, USPharmaceuticalsest. 1989Ionis PharmaceuticalsCarlsbad, CA, US · est. 1989

Ionis Pharmaceuticals: A US-based biotech firm specializing in RNA-targeted drug discovery for unmet needs.

Public · $1.3B796
Trevena
Trevena
Public$546.6M352007King of Prussia, PA, US
Board Member· Board

Leadership at Trevena

Barbara YanniBarbara YanniBoard Member
Robert LefkowitzRobert LefkowitzCo-Founder
Howard RockmanHoward RockmanBoard Member
Scott BraunsteinScott BraunsteinBoard Member
Lonnie MoulderLonnie MoulderBoard Member
Carrie L. BourdowCarrie L. BourdowBoard Member

Similar to Trevena

Tremeau PharmaceuticalsTremeau PharmaceuticalsConcord, MA, USPain Therapiesest. 2016Tremeau PharmaceuticalsConcord, MA, US · est. 2016

Massachusetts-based pharmaceutical company specializing in non-opioid pain therapies.

Private Equity · $115.2M11
TrigeminaTrigeminaMoraga, CA, USPain Treatmentsest. 2006TrigeminaMoraga, CA, US · est. 2006

Trigemina, Inc.: A US-based pharmaceutical company innovating non-opiate pain therapies.

Series A · $27.6M11
Tris PharmaTris PharmaMonmouth Junction, NJ, USPharmaceuticalsest. 2000Tris PharmaMonmouth Junction, NJ, US · est. 2000

Tris Pharma, a New Jersey-based medical organization, innovates drug delivery technologies and medicines for disease treatment.

Public · $141.6M350
Neurana PharmaceuticalsNeurana PharmaceuticalsSan Diego, CA, USPharmaceuticalsest. 2013Neurana PharmaceuticalsSan Diego, CA, US · est. 2013

Neurana Pharmaceuticals: A US-based specialty pharma company innovating treatments for CNS diseases.

Series A · $60M5

People Similar to Jake Nunn

Lau Eng BoonLau Eng BoonBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoSean JohSean JohBoard Member · KakaoLynn ThurberLynn ThurberBoard Member · JLL Income Property TrustJim O'NeillJim O'NeillBoard Member · The Thiel FoundationMarco MarinucciMarco MarinucciBoard Member · AEyeJerry ChenJerry ChenBoard Member · BlendG. Haig AriyanG. Haig AriyanCEO · Alex. Brown & SonsBill BrinkmanBill BrinkmanBoard Member · Gem Health